KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Finished Goods (2016 - 2021)

Biomarin Pharmaceutical's Finished Goods history spans 12 years, with the latest figure at $261.6 million for Q3 2021.

  • For the quarter ending Q3 2021, Finished Goods fell 20.79% year-over-year to $261.6 million, compared with a TTM value of $261.6 million through Sep 2021, down 20.79%, and an annual FY2020 reading of $313.6 million, up 22.57% over the prior year.
  • Finished Goods for Q3 2021 was $261.6 million at Biomarin Pharmaceutical, up from $253.3 million in the prior quarter.
  • The five-year high for Finished Goods was $330.3 million in Q3 2020, with the low at $129.6 million in Q2 2017.
  • Average Finished Goods over 5 years is $226.5 million, with a median of $220.9 million recorded in 2018.
  • Year-over-year, Finished Goods surged 70.09% in 2018 and then fell 20.79% in 2021.
  • Tracing BMRN's Finished Goods over 5 years: stood at $191.2 million in 2017, then grew by 17.76% to $225.2 million in 2018, then grew by 13.62% to $255.9 million in 2019, then rose by 22.57% to $313.6 million in 2020, then decreased by 16.56% to $261.6 million in 2021.
  • Per Business Quant, the three most recent readings for BMRN's Finished Goods are $261.6 million (Q3 2021), $253.3 million (Q2 2021), and $279.6 million (Q1 2021).